 | • レポートコード：MRC2303K108 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の調査レポートでは、世界の炎症性腸疾患（IBD）治療薬市場規模が、予測期間中（2022年-2027年）、CAGR 4.8％で増大すると予測されています。本レポートでは、炎症性腸疾患（IBD）治療薬の世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、疾患別（クローン病、潰瘍性大腸炎）分析、薬剤クラス別（TNF阻害剤、JAK阻害剤、アミノサリチル酸、副腎皮質ホルモン剤、その他）分析、投与経路別（経口、非経口）分析、エンドユーザー別（病院内薬局、オンライン薬局、小売薬局）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などについて調査・分析などの項目を掲載しています。並び、こちらのレポートには、Bristol-Myers Squibb Company、AbbVie Inc.、Allergan Therapeutics LLC、Bausch Health Companies Inc. (Salix Pharmaceuticals)、Rare Disease Therapeutics Inc.、Johnson & Johnson Services Inc.、UCB Inc.などの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の炎症性腸疾患（IBD）治療薬市場規模：疾患別 - クローン病における市場規模 - 潰瘍性大腸炎における市場規模 ・世界の炎症性腸疾患（IBD）治療薬市場規模：薬剤クラス別 - TNF阻害剤の市場規模 - JAK阻害剤の市場規模 - アミノサリチル酸の市場規模 - 副腎皮質ホルモン剤の市場規模 - その他炎症性腸疾患（IBD）治療薬の市場規模 ・世界の炎症性腸疾患（IBD）治療薬市場規模：投与経路別 - 経口型炎症性腸疾患（IBD）治療薬の市場規模 - 非経口型炎症性腸疾患（IBD）治療薬の市場規模 ・世界の炎症性腸疾患（IBD）治療薬市場規模：エンドユーザー別 - 病院内薬局における市場規模 - オンライン薬局における市場規模 - 小売薬局における市場規模 ・世界の炎症性腸疾患（IBD）治療薬市場規模：地域別 - 北米の炎症性腸疾患（IBD）治療薬市場規模 アメリカの炎症性腸疾患（IBD）治療薬市場規模 カナダの炎症性腸疾患（IBD）治療薬市場規模 メキシコの炎症性腸疾患（IBD）治療薬市場規模 … - ヨーロッパの炎症性腸疾患（IBD）治療薬市場規模 ドイツの炎症性腸疾患（IBD）治療薬市場規模 イギリスの炎症性腸疾患（IBD）治療薬市場規模 フランスの炎症性腸疾患（IBD）治療薬市場規模 … - アジア太平洋の炎症性腸疾患（IBD）治療薬市場規模 中国の炎症性腸疾患（IBD）治療薬市場規模 日本の炎症性腸疾患（IBD）治療薬市場規模 インドの炎症性腸疾患（IBD）治療薬市場規模 … - 南米/中東の炎症性腸疾患（IBD）治療薬市場規模 南アフリカの炎症性腸疾患（IBD）治療薬市場規模 ブラジルの炎症性腸疾患（IBD）治療薬市場規模 アルゼンチンの炎症性腸疾患（IBD）治療薬市場規模 … ・競争状況 ・市場機会・将来動向 |
The Inflammatory Bowel Disease (IBD) Therapeutics marketis projected to register a CAGR of 4.8% during the forecast period (2022-2027).
With the rise of COVID 19, there has been a rise in other complications that arise along with the infection. According to a report by Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-IBD) database in January 2022, adverse COVID 19 outcomes were associated with the age and other co morbidities among patients with IBD. The novel severe acute respiratory syndrome – related corona virus, upon entering the gastrointestinal tract, initiates activation of innate and adaptive immune responses. The onset of inflammatory reactions can supposedly induce intestinal damage in IBD patients. Also, a research article by Monteleone G., published in Journal of Crohn’s and colitis in March 2020 showed that the IBD patients undertaking immune suppressors are associated with greater risk of infections, even though there are no evidence to suggest that the COVID affects IBD patients more commonly than the general population. As per a review article in World journal of Gastroenterology by Sultan K., in October 2020, it was comprehended that many COVID 19 patients were found to develop gastrointestinal complaints. Older IBD patients with co morbidities such as hypertension, coronary heart disease, diabetes mellitus and obstructive lung disease are more susceptible to COVID 19 infection, as indicated by Neurath MF in an article published in the journal, Gut in July 2020. Thus, there is an increasing demand for Inflammatory Bowel Disease (IBD) Therapeutics market to manage further complications that could develop due to COVID 19.
The increasing occurrence of Crohn’s disease and Ulcerative colitis is the major driver which is predicted to boost the growth of the market. According to a report by Center for Disease Control and Prevention (CDC) published in April 2021, on the World IBD Day (May 19), the number of people affected by IBD is around 7 million around the world. The report also stated that the rate of prevalence of the disease has significantly increased during the last two decades. The prevalence of chronic health conditions such as cancer, arthritis, migraine, and other cardiovascular, respiratory, kidney and liver diseases are higher in IBD patients than non IBD patients. In older population (>66 years old), patients with IBD were more susceptible to hospitalization for hip fractures. Also, they were found to have 30 day readmissions and longer hospital stays. Studies being done on the treatment of IBD for prevention of such instances are a great boost to the development of the market in the upcoming period.
Increase in the approval of biologics and the presence of robust pipeline products is expected to propel the growth of the market. As per a study by Alulis S., published in BMC Health Services Research journal in August 2021, the IBD patients receiving biologic treatments were found to have higher average annual healthcare costs. The increasing use of biologic therapies in IBD patients provides lucrative opportunities for market growth attributing to the vast costs of biologics. The improving demand for IBD medication is expected to drive the market growth. However, lack of awareness among people about IBD is expected to limit the growth of the market.
Inflammatory Bowel Disease Therapeutics Market Trends
The JAK inhibitors Segment is Expected to Hold a Major Market Share in the Inflammatory Bowel Disease (IBD) Therapeutics Market.
The Janus Kinase (JAK) inhibitors are a major fraction of the drug classes used in the treatment of IBD. A study by Rogler G published in Journal of Crohn’s and colitis in November 2019, showed that JAK inhibitors are an attractive treatment option for Crohn’s Disease and Ulcerative colitis. The newer classes of orally administered JAK inhibitors are being clinically tested.
As per above source, phase II studies are being conducted to study the efficacy of the JAK inhibitors, filgotinib and upadacitinib. Consequently phase III programmes for both the drugs have been initiated. The significance of the research on the JAK inhibitors places a special focus which could have a major impact on the growth of the market.
Recently, combination therapies are being studied as the crucial resource for the treatment of refractory IBD. As discussed in a article by Parigi TL published in Expert Review of Clinical Immunology in December 2021, JAK inhibitors in combination with other biologic treatment methods, have illustrated adequate safety profile and comparatively good efficacy.
Significant discoveries in the treatment of IBD, especially the use of biologics, is expected to increase the Inflammatory Bowel Disease (IBD) Therapeutics market. JAK inhinitors, often known as oral biologics, are antibodies that are synthesized in vivo, that act specifically by stopping certain inflammation causing proteins. There is a large importance placed on the research of using JAK inhibitors and the magnitude of the research work being done on further combination therapy is subtantial. These factors are expected to have a significant impact on the growth of the IBD treatment market in the upcoming period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period.
The regions of high income, specifically the United States has been found to have the largest number of IBD cases reported. The United States was found to have the highest age standardised prevaence rate among the world. A systemic analysis published in Lancet journal for Gastroenterology and Hepatology in October 2019 revealed that United States harboured about one fourth of the global IBD population. The increased awareness and advanced treatment rates account for the larger disposition of the disease in the North American region. The increase in the prescription rates of the innovative medicines is expected to drive the demand for the IBD therapeutics market in the North American region. Increase in research and development in the clinical stage companies in the novel treatments for the disease is predicted to boost the growth of IBD therapeutics market in the region. In a study by Alatab, as published in Lancet journal for Gastroenterology and Hepatology in January 2020, it was found that the prevalence of the disease ranged from 252 to 439 cases per 100,000 population in the United States. There also has been an increase in the number of cases in the Asia Pacific, owing to rapid industrialization and improved awareness among the population. The Asia Pacific region, is expected to be fastest growing market due to larger consumer base and increasing approval of IBD therapeutics.
Inflammatory Bowel Disease Therapeutics Market Competitor Analysis
The Inflammatory Bowel Disease (IBD) Therapeutics market is fragmented competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Bristol-Myers Squibb Company, AbbVie Inc., Allergan Therapeutics LLC, Bausch Health Companies Inc. (Salix Pharmaceuticals), Rare Disease Therapeutics Inc., Johnson & Johnson Services Inc., Janssen Biotech, Inc., UCB Inc. and others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and market definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Research on IBD Treatment
4.2.2 Increasing Occurrence of Crohn’s Disease and Ulcerative Colitis
4.3 Market Restraints
4.3.1 Strict Drug Regulatory Policies
4.3.2 Lack of awareness among people
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Disease
5.1.1 Crohn’s disease
5.1.2 Ulcerative colitis
5.2 By Drug Class
5.2.1 TNF inhibitors
5.2.2 JAK inhibitors
5.2.3 Aminosalicylates
5.2.4 Corticosteroids
5.2.5 Others
5.3 By Route of administration
5.3.1 Oral
5.3.2 Parenteral
5.4 By End User
5.4.1 Hospital pharmacies
5.4.2 Online pharmacies
5.4.3 Retail pharmacies
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle-East
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle-East
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bristol-Myers Squibb Company
6.1.2 AbbVie Inc.
6.1.3 Allergan Therapeutics LLC
6.1.4 Bausch Health Companies Inc. (Salix Pharmaceuticals)
6.1.5 Rare Disease Therapeutics Inc.
6.1.6 Johnson & Johnson Services Inc.
6.1.7 UCB Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS